APUS
Apimeds Pharmaceuticals US
APUS
APUS
6 hedge funds and large institutions have $490K invested in Apimeds Pharmaceuticals US in 2025 Q2 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
6
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$23.5K | |
| 2 | +$21.1K | |
| 3 | +$5.55K | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$52 |
| 5 |
JP Morgan Chase
New York
|
+$9 |
Top Sellers
No sellers this quarter
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
YAG
1
Yorkville Advisors Global
Mountainside,
New Jersey
| $440K |
|
|||
2
Citadel Advisors
Miami,
Florida
| $23.5K |
|
|||
3
Goldman Sachs
New York
| $21.1K |
|
|||
|
TRCT
4
Tower Research Capital (TRC)
New York
| $5.55K |
|
|||
|
5
Bank of America
Charlotte,
North Carolina
| $52 |
|
|||
|
6
JP Morgan Chase
New York
| $9 |
|